Filing Flows › Prime Medicine (PRME) › R&D spending
Prime Medicine (PRME) R&D spending by quarter
Prime Medicine's R&D spending was $34.7M in Q4 2025 (fourth quarter 2025), -21% from Q3 2025. Over the last 5 quarters it ranged from $34.1M (Q4 2024) to $44.0M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q4 2025 | $34.7M | -21% | +2% |
| Q3 2025 | $44.0M | +6% | — |
| Q2 2025 | $41.4M | +2% | — |
| Q1 2025 | $40.6M | +19% | — |
| Q4 2024 | $34.1M | — | — |
Q4 2025 at a glance
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Prime Medicine's R&D spending?
Prime Medicine's R&D spending was $34.7M in Q4 2025 (fourth quarter 2025), -21% from Q3 2025.
How has Prime Medicine's R&D spending changed?
Over the last 5 quarters it ranged from $34.1M (Q4 2024) to $44.0M (Q3 2025).